The popular gene-editing tool CRISPR can tag proteins in the brain, illuminating the whereabouts of autism candidates.

An early-stage treatment for eye cancer reverses memory problems in a mouse model of fragile X syndrome.

Watch the replay of Claudia Bagni’s webinar, in which she described molecular pathways that are impaired in fragile X syndrome, autism and schizophrenia. She also discussed mouse and fly models, as well as human cells.

Boosting levels of the fragile X protein FMRP in astrocytes reverses features of fragile X syndrome in mice.

Autism researchers are sharpening their statistical tools to make sense of the growing pool of autism genes.

Researchers have discovered an enzyme that lowers brain levels of FMRP, the protein missing in people with fragile X syndrome. Blocking the enzyme may ease fragile X symptoms in people with the disorder who have low levels of FMRP and mild symptoms.

An autism-linked gene controls the number of neurons in the developing brain. Freda Miller and David Kaplan say the finding points to a new role for the gene in the early embryo.

Treatments for fragile X syndrome may be more successful if they block direct targets of the key missing protein, says Eric Klann.

Blocking an enzyme involved in learning and memory corrects brain abnormalities and improves memory in fly and mouse models of fragile X syndrome.

Drugs developed to treat fragile X syndrome may also work for autism because both disorders feature defects at neuronal junctions, suggests a paper published 12 January in Nature Neuroscience.